Randomised, double-blind, parallel group comparison of Ashitaba (Angelica Keiskei) chalcone effects on visceral fat areas and waist circumference of overweight persons

References

• Burri L, Thoresen GH, Berge RK. 2010. The role of PPARα activation in liver and muscle. PPAR Res. 2010:1–11. doi:10.1155/2010/542359.
   Web of Science ®Google Scholar
• Caesar LK, Cech NB. 2016. A review of the medicinal uses and pharmacology of Ashitaba. Planta Med. 82(14):1236–1245. doi:10.1055/s-0042-110496.
   PubMed Web of Science ®Google Scholar
• Castelnuovo G, Pietrabissa G, Manzoni GM, Cattivelli R, Rossi A, Novelli M, Varallo G, Molinari E. 2017. Cognitive behavioral therapy to aid weight loss in obese patients: current perspectives. Psychol Res Behav Manag. 10:165–173. doi:10.2147/PRBM.S113278.
   PubMed Web of Science ®Google Scholar
• Caveney E, Caveney BJ, Somaratne R, Turner JR, Gourgiotis L. 2011. Pharmaceutical interventions for obesity: a public health perspective. Diabetes Obes Metab. 13(6):490–497. doi:10.1111/j.1463-1326.2010.01353.x.
   PubMed Web of Science ®Google Scholar
• Consumer Affairs Agency, Regarding labeling permission for Foods for Specified Health Uses. 2014. Attachment 2: points to consider when preparing an application form for a Food for Specified Health Uses application. [in Japanese]
   Google Scholar
• Fabbrini E, Sullivan S, Klein S. 2010. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 51(2):679–689. doi:10.1002/hep.23280.
   PubMed Web of Science ®Google Scholar
• Fujii H, Iwase M, Ohkuma T, Ogata-Kaizu S, Ide H, Kikuchi Y, Idewaki Y, Joudai T, Hirakawa Y, Uchida K, et al. 2013. Impact of dietary fiber intake on glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry. Nutr J. 12(1):159. doi:10.1186/1475-2891-12-159.
   PubMedGoogle Scholar
• Geurts KAM, Woodcock-Nekeman S, Hummel M, Dietvorst CAW, van Rossum EFC, Berk KA. 2023. The effect of including eHealth in dietary interventions for patients with type 2 diabetes with overweight or obesity: a systematic review. Nutrients. 15(17):3776. doi:10.3390/nu15173776.
   PubMed Web of Science ®Google Scholar
• Gradidge PJ, Jaff NG, Norris SA, Toman M, Crowther NJ. 2022. The negative association of lower body fat mass with cardiometabolic disease risk factors is partially mediated by adiponectin. Endocr Connect. 11(12):e220156. doi:10.1530/EC-22-0156.
   PubMed Web of Science ®Google Scholar
• Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, et al. 2007. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol. 27(3):635–641. doi:10.1161/01.ATV.0000256469.06782.d5.
   PubMed Web of Science ®Google Scholar
• Hooper L, Abdelhamid A, Moore HJ, Douthwaite W, Skeaff CM, Summerbell CD. 2012. Effect of reducing total fat intake on body weight: systematic review and meta-analysis of randomised controlled trials and cohort studies. BMJ. 345:e7666–e7666. doi:10.1136/bmj.e7666.
   PubMed Web of Science ®Google Scholar
• Hursel R, Viechtbauer W, Westerterp-Plantenga MS. 2009. The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int J Obes (Lond). 33(9):956–961. doi:10.1038/ijo.2009.135.
   PubMed Web of Science ®Google Scholar
• Igel LI, Kumar RB, Saunders KH, Aronne LJ. 2017. Practical use of pharmacotherapy for obesity. Gastroenterology. 152(7):1765–1779. doi:10.1053/j.gastro.2016.12.049.
   PubMed Web of Science ®Google Scholar
• Jain SH, Massaro JM, Hoffmann U, Rosito GA, Vasan RS, Raji A, O’Donnell CJ, Meigs JB, Fox CS. 2009. Cross-sectional associations between abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham heart study. Diabetes Care. 32(5):903–908. doi:10.2337/dc08-1733.
   PubMed Web of Science ®Google Scholar
• Japan Society for the Study of Obesity (JSSO). 2016. Guidelines for the management of obesity disease 2016. Osaka (Japan): Life Science Publishing Co., Ltd. [in Japanese]
   Google Scholar
• Kersten S, Stienstra R. 2017. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie. 136:75–84. doi:10.1016/j.biochi.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Kil YS, Pham ST, Seo EK, Jafari M. 2017. Angelica keiskei, an emerging medicinal herb with various bioactive constituents and biological activities. Arch Pharm Res. 40(6):655–675. doi:10.1016/j.biochi.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Kim JB, Spiegelman BM. 1996. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10(9):1096–1107. doi:10.1101/gad.10.9.1096.
   PubMed Web of Science ®Google Scholar
• Kishida K, Kim KK, Funahashi T, Matsuzawa Y, Kang HC, Shimomura I. 2011. Relationships between circulating adiponectin levels and fat distribution in obese participants. J Atheroscler Thromb. 18(7):592–595. doi:10.5551/jat.7625.
   PubMed Web of Science ®Google Scholar
• Koutnikova H, Genser B, Monteiro-Sepulveda M, Faurie JM, Rizkalla S, Schrezenmeir J, Clement K. 2019. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 9(3):e017995. doi: 10.1136/bmjopen-2017-017995.
   Google Scholar
• Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, et al. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50(9):2094–2099. doi:10.2337/diabetes.50.9.2094.
   PubMed Web of Science ®Google Scholar
• Maronpot RR. 2015. Toxicological assessment of Ashitaba Chalcone. Food Chem Toxicol. 77:111–119. doi:10.1016/j.fct.2014.12.021.
   PubMed Web of Science ®Google Scholar
• Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’Rahilly S, et al. 2006. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 58(4):726–741. doi:10.1124/pr.58.4.5.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labor and Welfare. 2012. Health Japan 21 second ver. Tokyo (Japan): Ministry of Health, Labor and Welfare. [in Japanese]
   Google Scholar
• Ministry of Health, Labor and Welfare. 2020. National health and nutrition survey in Japan, 2019. Tokyo (Japan): Ministry of Health, Labor and Welfare. [in Japanese]
   Google Scholar
• Morsali M, Poorolajal J, Shahbazi F, Vahidinia A, Doosti-Irani A. 2023. Pharmaceutical therapies for the treatment of obesity: a network meta-analysis. Clin Ther. 45(7):671–678. doi:10.1016/j.clinthera.2023.06.003.
   PubMed Web of Science ®Google Scholar
• Nagata J, Morino T, Saito M. 2007. Effects of dietary Angelica keiskei on serum and liver lipid profiles, and body fat accumulations in rats. J Nutr Sci Vitaminol (Tokyo). 53(2):133–137. doi:10.3177/jnsv.53.133.
   PubMed Web of Science ®Google Scholar
• Numao N, Katayama Y, Hayashi Y, Lee D. 2003. Tanaka K. Lipid metabolism during aerobic exercise comparison of obesity with different visceral fat areas. J Jpn Soc Study Obes. 10(2):183–189.
   Google Scholar
• Ogawa H, Ohno M, Baba K. 2005. Hypotensive and lipid regulatory actions of 4-hydroxyderricin, a chalcone from Angelica keiskei, in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 32(1–2):19–23. doi:10.1111/j.1440-1681.2005.04147.x.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Okada Y, Kamisako T, Baba K. 2007. Beneficial effect of xanthoangelol, a chalcone compound from Angelica keiskei, on lipid metabolism in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 34(3):238–243. doi:10.1111/j.1440-1681.2007.04578.x.
   PubMed Web of Science ®Google Scholar
• Ohkura N, Atsumi G, Ohnishi K, Baba K, Taniguchi M. 2018. Possible antithrombotic effects of Angelica keiskei (Ashitaba). Pharmazie. 73(6):315–317. doi:10.1691/ph.2018.8370.
   PubMed Web of Science ®Google Scholar
• Ohnogi H, Kudo Y, Tahara K, Sugiyama K, Enoki T, Hayami S, Sagawa H, Tanimura Y, Aoi W, Naito Y, et al. 2012. Six new chalcones from Angelica keiskei inducing adiponectin production in 3T3-L1 adipocytes. Biosci Biotechnol Biochem. 76(5):961–966. doi:10.1271/bbb.110976.
   PubMed Web of Science ®Google Scholar
• Ohta M, Fujinami A, Kobayashi N, Amano A, Ishigami A, Tokuda H, Suzuki N, Ito F, Mori T, Sawada M, et al. 2015. Two chalcones, 4-hydroxyderricin and xanthoangelol, stimulate GLUT4-dependent glucose uptake through the LKB1/AMP-activated protein kinase signaling pathway in 3T3-L1 adipocytes. Nutr Res. 35(7):618–625. doi:10.1016/j.nutres.2015.05.010.
   PubMed Web of Science ®Google Scholar
• Ohta M, Fujinami A, Oishi K, Kobayashi N, Ohnishi K, Ohkura N. 2019. Ashitaba (Angelica Keiskei) exudate prevents increases in plasminogen activator inhibitor-1 induced by obesity in Tsumura Suzuki obese diabetic mice. J Diet Suppl. 16(3):331–344. doi:10.1080/19390211.2018.1458366.
   PubMed Web of Science ®Google Scholar
• Petridou A, Siopi A, Mougios V. 2019. Exercise in the management of obesity. Metabolism. 92:163–169. doi:10.1016/j.metabol.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Phillips BT, Shikora SA. 2018. The history of metabolic and bariatric surgery: development of standards for patient safety and efficacy. Metabolism. 79:97–107. doi:10.1016/j.metabol.2017.12.010.
   PubMed Web of Science ®Google Scholar
• Shaik Mohamed Sayed UF, Moshawih S, Goh HP, Kifli N, Gupta G, Singh SK, Chellappan DK, Dua K, Hermansyah A, Ser HL, et al. 2023. Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management. Front Pharmacol. 14:1182937. doi:10.3389/fphar.2023.1182937.
   PubMed Web of Science ®Google Scholar
• Siddiqui SA, Azmy Harahap I, Suthar P, Wu YS, Ghosh N, Castro-Muñoz R. 2023. A comprehensive review of phytonutrients as a dietary therapy for obesity. Foods. 12(19):3610. doi:10.3390/foods12193610.
   PubMed Web of Science ®Google Scholar
• Talenezhad N, Mohammadi M, Ramezani-Jolfaie N, Mozaffari-Khosravi H, Salehi-Abargouei A. 2020. Effects of l-carnitine supplementation on weight loss and body composition: a systematic review and meta-analysis of 37 randomized controlled clinical trials with doseresponse analysis. Clin Nutr ESP EN. 37:9–23. doi: 10.1016/j.clnesp.2020.03.008.
   Google Scholar
• Wadden TA, Webb VL, Moran CH, Bailer BA. 2012. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation. 125(9):1157–1170. doi:10.1161/CIRCULATIONAHA.111.039453.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kadowaki T. 2009. Metabolic syndrome and adiponectin. Inflammation and Immunity. 17(2):191–198.
   PubMedGoogle Scholar
• Yamauchi T. 2003. Regulatory mechanism of sugar and lipid metabolism by adipocytes. J Jpn Soc Study Obes. 9(2):114–120.
   Google Scholar
• Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7(8):941–946. doi:10.1038/90984.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, et al. 2003. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 423(6941):762–769. doi:10.1038/nature01705.
   PubMed Web of Science ®Google Scholar
• Yoshiike N. 2014. Epidemiology of obesity in Japanese. Jpn J Clin Exp Med. 91(6):717–720.
   Google Scholar
• Zhang T, Yamashita Y, Yasuda M, Yamamoto N, Ashida H. 2015. Ashitaba (Angelica keiskei) extract prevents adiposity in high-fat diet-fed C57BL/6 mice. Food Funct. 6(1):135–145. doi:10.1039/c4fo00525b.
   PubMed Web of Science ®Google Scholar